Akebia Therapeutics Reports Strong Q4 & FY25 Results, Significant Cash Increase, and Vafseo Commercial Momentum

summarizeSummary

Akebia Therapeutics reported strong Q4 and full-year 2025 financial results, including significant revenue growth, a reduced net loss, and a substantial increase in cash, extending its operational runway for over two years. The company also highlighted positive commercial momentum for Vafseo and progress in its rare kidney disease pipeline.

check_boxKey Events

• Strong Q4 and Full Year 2025 Financial Results

  Total revenues increased to $57.6 million in Q4 2025 (from $46.5 million in Q4 2024) and $236.2 million for full-year 2025 (from $160.2 million in full-year 2024). Net loss significantly decreased to $12.2 million in Q4 2025 (from $22.8 million in Q4 2024) and $5.3 million for full-year 2025 (from $69.4 million in full-year 2024).

• Significant Increase in Cash Position and Extended Runway

  Cash and cash equivalents surged to $184.8 million as of December 31, 2025, up from $51.9 million at the end of 2024. The company expects its existing cash resources to fund operations for at least two years.

• Positive Vafseo Commercial Launch Trends

  Vafseo net product revenues reached $6.2 million in Q4 2025 and $45.8 million for the full-year 2025. Patient access expanded to 290,000, and first refill adherence rates improved to 91% in Q4 from 75% earlier in the year, driven by in-center observed dosing protocols.

• Advancement of Rare Kidney Disease Pipeline

  Enrollment is underway for the praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS). A Phase 2 rare kidney disease basket trial for AKB-097 is planned for 2H 2026, with initial data expected in 2027. A Phase 1 study for AKB-9090 is also expected to begin in 1H 2026.

auto_awesomeAnalysis

Akebia Therapeutics delivered a strong financial performance for Q4 and full-year 2025, marked by substantial revenue growth and a significant reduction in net loss. The company's cash position dramatically improved, extending its operational runway for at least two years, which is a critical de-risking factor for a life sciences company. Positive commercial trends for Vafseo, including increased patient access and improved adherence rates, suggest growing market acceptance. Additionally, the advancement of multiple pipeline programs in rare kidney diseases indicates future growth potential, despite anticipated generic competition for Auryxia in 2026.